The Covid Pandemic Drives Pfizer's 2022 Revenue to a Record $100 Billion
Source: CNBC
Pfizer sold $37.8 billion of its Covid vaccine last year, a small increase of 3% compared with 2021 as demand for the shots slowed. Sales of Paxlovid, however, surged to $18.9 billion in 2022, which was the first full year the antiviral pill was available. Pfizer expects its revenue to decline in 2023 by as much as 33% to a range of $67 billion to $71 billion as the world emerges from the pandemic and demand for its blockbuster Covid drugs slows.
The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizers earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill Paxlovid, the company reported Tuesday.
The vaccine accounted for $37.8 billion, up just 3% from 2021, of Pfizers total sales as demand for the shots slowed. But sales of its blockbuster antiviral treatment made up for that softening, surging to $18.9 billion in 2022, the first full year that Paxlovid was on the market.
Pfizers combined sales from its Covid vaccine and antiviral treatment generated more revenue last year than it had in total sales in 2019, before the pandemic became a global crisis that killed more than 6.8 million people and upended world markets. Those results wont be repeated this year...
Read more: https://www.cnbc.com/2023/01/31/the-covid-pandemic-drives-pfizers-2022-revenue-to-a-record-100-billion.html
cstanleytech
(26,281 posts)actual costs correct?
appalachiablue
(41,123 posts)been deducted from revenue (sales). Thanks for posting.
Investopedia: What Is Revenue? Revenue is the money generated from normal business operations, calculated as the average sales price times the number of units sold. It is the top line (or gross income) figure from which costs are subtracted to determine net income. Revenue is also known as sales on the income statement...https://www.investopedia.com/terms/r/revenue.asp